Boston Scien Cp - BSX STOCK NEWS

Boston Scientific (NYSE: BSX) has announced a definitive agreement to acquire Bolt Medical, developer of an intravascular lithotripsy (IVL) advanced laser-based platform for treating coronary and peripheral artery disease. The acquisition includes an upfront payment of $443 million for the 74% stake not yet owned, plus potential regulatory milestone payments of up to $221 million.

Boston Scientific, which already holds a 26% equity stake in Bolt Medical since helping establish it in 2019, aims to expand its cardiovascular portfolio with this complementary calcium modification platform. The Bolt IVL™ system uses novel lithotripsy technology to fracture calcium through acoustic pressure waves inside a balloon catheter.

Bolt Medical recently completed the RESTORE ATK and BTK pivotal clinical trials and received FDA approval to commence the global FRACTURE IDE clinical trial for coronary arterial disease treatment. The transaction is expected to close in first half 2025 and be slightly dilutive to adjusted EPS in 2025.

Sherpa Healthcare Partners has appointed Raymond W. Cohen as Venture Partner. Cohen, a veteran healthcare executive, recently served as CEO and board member of Axonics, a medical technology company he co-founded in 2013 and took public in 2018. Under his leadership, Axonics achieved notable recognition, ranking first in both the 2021 Deloitte Technology Fast 500™ and 2022 Financial Times fastest-growing companies in the Americas list.

Cohen retired as CEO following Boston Scientific 's (NYSE: BSX) $3.7 billion acquisition of Axonics in November 2024. Before Axonics, he was CEO of Vessix Vascular, which was also acquired by Boston Scientific in 2012. The appointment aims to leverage Cohen's extensive experience in growing MedTech companies to support Sherpa's investment activities in innovative healthcare technologies.

Boston Scientific (NYSE: BSX) has announced two upcoming investor events. First, the company will participate in the 43rd Annual J.P. Morgan Healthcare Conference on January 13, 2025, in San Francisco. CEO Mike Mahoney will present at 5:15 p.m. PT, joined by CFO Dan Brennan and CMO Dr. Kenneth Stein for a Q&A session.

Additionally, BSX will host its fourth quarter 2024 earnings call on February 5, 2025, at 8:00 a.m. ET. Financial results will be released prior to the call. Both events will be accessible via webcast on the company's investor relations website, with replays available approximately one hour after each event.

Boston Scientific (NYSE: BSX) has announced a definitive agreement to acquire Intera Oncology Inc., gaining access to the Intera 3000 Hepatic Artery Infusion Pump and floxuridine chemotherapy drug. The acquisition targets liver cancer treatment, particularly for metastatic colorectal cancer patients. The Intera 3000 pump, the only FDA-approved constant flow implantable pump for HAI therapy in the US, delivers continuous chemotherapy directly to the liver. Clinical trials have shown significant improvements in tumor response, progression time, and survival rates compared to systemic chemotherapy. The transaction is expected to close in first half 2025, with immaterial impact on adjusted EPS but more dilutive on GAAP basis.

Boston Scientific announced positive three-year results from the OPTION clinical trial of its WATCHMAN FLX™ Left Atrial Appendage Closure Device. The study compared the device to oral anticoagulation (OAC) for stroke risk reduction in patients with non-valvular atrial fibrillation following cardiac ablation. The device showed superior bleeding risk reduction (8.5% vs 18.1%) and non-inferior efficacy in preventing death, stroke, or systemic embolism (5.4% vs 5.8%) compared to OAC. The trial included 1,600 patients across 114 sites, with approximately 60% receiving the implant 90-180 days post-ablation and 40% during the same procedure.

Boston Scientific (NYSE: BSX) has completed its acquisition of Axonics (Nasdaq: AXNX), a medical technology company specializing in devices for urinary and bowel dysfunction treatment. The acquisition, valued at $3.7 billion in equity value and $3.3 billion in enterprise value, was completed at $71 cash per share. The deal expands Boston Scientific's Urology business into sacral neuromodulation, a high-growth market. The transaction is expected to be immaterial to adjusted earnings per share in 2024 and 2025, becoming accretive thereafter, though potentially less accretive or more dilutive on a GAAP basis due to amortization and acquisition costs.

SoniVie , a medical device company developing a renal denervation system for hypertension treatment, has appointed Raymond W. Cohen as Chairman of its Board of Directors. Cohen, who is retiring from Axonics following its $3.7 billion sale to Boston Scientific , brings significant experience in the medical technology sector. He previously served as CEO of Axonics, which he co-founded in 2013 and led to become the top-ranked company in the 2021 Deloitte Technology Fast 500™. Cohen also has relevant expertise in renal denervation from his time as CEO of Vessix Vascular, which was acquired by Boston Scientific in 2012.

Boston Scientific (NYSE: BSX) has announced its participation in the 2024 UBS Global Healthcare Conference scheduled for Tuesday, November 12, 2024. The company will be represented by Nick Spadea-Anello, president of Electrophysiology, and Jon Monson, senior vice president of Investor Relations, who will engage in a 35-minute Q&A session starting at 7:15 a.m. PT / 10:15 a.m. ET. The session will be available via live webcast, with a replay accessible approximately one hour after the event's conclusion on the company's investor relations website.

Boston Scientific (NYSE: BSX) has announced a definitive agreement to acquire Cortex Inc., a private medical technology company specializing in diagnostic mapping solutions for atrial fibrillation (AF). The key asset is the OptiMap™ System, which received FDA 510(k) clearance in 2023. The system uses a basket catheter and proprietary algorithm to identify AF sources, enabling targeted ablation strategies.

Clinical data from the FLOW-AF trial showed OptiMap-guided treatment improved freedom from AF by 51% compared to conventional therapy. The acquisition is expected to close in first half 2025, with immaterial impact on adjusted EPS and slight GAAP dilution. The ongoing RESOLVE-AF trial is evaluating the system's effectiveness across 300 patients globally.